BGY 1601
Alternative Names: BGY-1601; BGY-1601-VT; LadybiomeLatest Information Update: 13 Aug 2026
At a glance
- Originator Nexbiome Therapeutics
- Class Anti-inflammatories; Bacteria; Probiotics
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Vaginitis
Most Recent Events
- 20 Feb 2026 Nexbiome Therapeutics terminates the Phase-I/II clinical trials in Vaginitis in Germany and France (Vaginal) due toSponsor Decision (CTIS2023-508958-26-00)
- 14 Jun 2024 Phase-I/II clinical trials in Vaginitis in France (Vaginal) (Nexbiome therapeutics pipeline, June 2024)
- 12 Jun 2024 Nexbiome therapeutics plans a phase I/II study for Bacterial vaginosis and Vulvovaginal candidiasis in unknown location in July 2024 (Vaginal, tablet) (NCT06450990)